Last reviewed · How we verify
UREA C 13
UREA C 13 is a marketed drug with a key composition patent expiring in 2028. Its mechanism of action involves binding to specific proteins or receptors, which may offer a unique therapeutic profile. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | UREA C 13 |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
Common side effects
Key clinical trials
- Gut Microbiome-Metabolome Profiling in H. Pylori-SIBO Comorbidity
- Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors (PHASE2)
- Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) (PHASE1,PHASE2)
- Gastric Cancer Prevention for Indigenous Peoples (NA)
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab (PHASE2)
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (PHASE2)
- Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study (NA)
- Metabolic Processes in Adults and Adolescents With Autism Spectrum Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UREA C 13 CI brief — competitive landscape report
- UREA C 13 updates RSS · CI watch RSS